Auburn Research Day 2022

Cl i n i ca l Case Repor t | Med i ca l St udent Posttraumatic Posterior Shoulder Instability Status Post Latarjet-Bristow for Bony Bankart with Recovered Axillary Nerve Palsy: A Case Report 78

Timothy Kanne 1 ; Dr. Bassem Elhassan 2 VCOM Auburn 1 ; Mayo Clinic at Rochester, MN 2

While anterior shoulder dislocations are relatively common, posterior shoulder dislocations are relatively rare. Even rarer are patients that have had both anterior and posterior dislocations in the same shoulder. While Latarjet-Bristow procedures are not uncommon following anterior shoulder dislocations, there are no known reported cases of posttraumatic posterior shoulder instability status post Latarjet procedure. In this case, a 17-year-old male who had posterior shoulder instability status post Latarjet procedure underwent a posterior shoulder reconstruction with ipsilateral medial spine of

scapula bone graft for posterior inferior glenoid augmentation is described. The surgical technique and review of current literature regarding ipsilateral anterior and posterior shoulder dislocations is also presented.

B i omed i ca l Resea rch | Gr adua te/Undergr adua te St udent 3D Printing Drug Delivery Technology for Atherosclerosis 79

Rachel Parise 1 ; R. Jayachandra Babu 1 ; Jack Deruiter 1 ; Kamal Dua 2,3 ; Muralikrishnan Dhanasekaran 1 1 Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University; 2 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia; 3 Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, Australia

3D printing drug delivery systems can be advantageous over traditional drug delivery systems because of the ability to create a more personalized and specific patient regimen based on the patient’s characteristics and disease. The future of 3D printed drug delivery could enhance drug efficacy versus traditional dosing methods. The types of 3D printers used for pharmaceutical dosage forms are stereolithography (SLA), selective laser sintering (SLS), selective laser-induced etching (SLE), semi-solid extrusion (SSE), 3D inkjet-based printers, fused deposition modeling (FDM), and pellet additive manufacturing (PAM). Atherosclerosis is a common progressive disease of the arteries occurring more frequently in older adults. Risk factors for atherosclerosis include high levels of low-density lipoprotein (LDL), decreased high-density lipoprotein (HDL), high total cholesterol (TC) and triglycerides (TG), environmental factors, and infection or injury-induced metabolic abnormalities. Currently, oral statin drug therapy is first line for lowering LDL in those at risk for atherosclerotic disease because of enhanced drug efficacy over alternative pharmacologic options. The existing oral drug therapies for atherosclerosis include the statin drug class, ezetimibe, bempedoic acid, gemfibrozil, fenofibrate, fish oils, and niacin. Problems with oral statin therapy as well as other lipid-lowering

therapies include first-pass hepatic metabolism, low bioavailability, numerous drug interactions, and adverse drug reactions. Some of these problems can be addressed by the use of novel 3D printing drug delivery technologies to produce customized, patient specific, and fast dissolvable dosage forms. Novel 3D printing drug delivery systems has the potential to improve health outcomes in patients with atherosclerosis by individualizing dosing regimens for each patient which can improve existing oral therapy side effects and increase drug efficacy. 3D drug delivery printing may also be more cost-effective compared to oral drug delivery based upon the manufacturing processes, dosing specificity, and through improved efficacy.

45 2022 Via Research Recognit ion Day